Vor Biopharma (NASDAQ:VOR) Given Buy Rating at HC Wainwright

Vor Biopharma (NASDAQ:VOR)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $31.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 118.46% from the stock’s previous close.

A number of other research firms also recently commented on VOR. Wall Street Zen downgraded shares of Vor Biopharma from a “hold” rating to a “sell” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research note on Wednesday, January 21st. Jefferies Financial Group raised shares of Vor Biopharma to a “strong-buy” rating in a research note on Thursday, April 30th. Wedbush upped their price objective on shares of Vor Biopharma from $15.00 to $18.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, Wells Fargo & Company started coverage on shares of Vor Biopharma in a research note on Thursday, March 19th. They set an “overweight” rating and a $30.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $42.25.

Vor Biopharma Trading Down 3.0%

VOR traded down $0.44 during trading on Monday, hitting $14.19. The company’s stock had a trading volume of 387,974 shares, compared to its average volume of 992,033. The firm’s 50 day moving average price is $15.11 and its 200-day moving average price is $14.13. Vor Biopharma has a twelve month low of $3.30 and a twelve month high of $65.80.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings results on Monday, March 30th. The company reported $307.61 earnings per share for the quarter. As a group, analysts forecast that Vor Biopharma will post -3.56 EPS for the current year.

Insider Transactions at Vor Biopharma

In related news, Director Ra Capital Management, L.P. sold 165,150 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $15.77, for a total transaction of $2,604,415.50. Following the completion of the sale, the director owned 2,402,095 shares of the company’s stock, valued at approximately $37,881,038.15. This represents a 6.43% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have sold 3,002,903 shares of company stock worth $49,412,176. 0.45% of the stock is currently owned by corporate insiders.

Institutional Trading of Vor Biopharma

A number of institutional investors and hedge funds have recently bought and sold shares of VOR. RA Capital Management L.P. increased its holdings in Vor Biopharma by 172.7% in the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock valued at $70,697,000 after purchasing an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. increased its holdings in Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Vor Biopharma in the 4th quarter valued at $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in Vor Biopharma in the 4th quarter valued at $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in Vor Biopharma in the 4th quarter valued at $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).